China channel feed – Endpoints News

China channel feed

Shortage of monkeys slowed down Eli Lilly's Covid-19 antibody partner. And it's a problem for everyone

5 years ago

A year after stunning China OK, Shanghai Alzheimer's drugmaker set to enroll first US patient — and the stakes are huge

5 years ago

JW Therapeutics hauls in $300M IPO just as liso-cel-inspired CAR-T nears the finish line in China

5 years ago

Eyeing commercialization, a Shanghai-based CAR-T startup nabs a $186M megaround

5 years ago

Perceptive recruits A-list investors to back its in-house China startup with a mammoth $310M raise

5 years ago

Chinese rare disease player inks first deal around narcolepsy drug Wakix after grabbing $80M to build an ecosystem

5 years ago

The disruptors at EQRx have their eyes on the PD-(L)1 market — teeing up $150M cash to grab 2 backbone therapies from China

5 years ago

Chinese investors wager $105M on an IPO-bound biotech looking to push RNAi as mainstream cancer therapy

5 years ago

Out to pioneer gene editing in China, EdiGene bags $67M to begin clinical testing for β-thalassemia therapy, universal CAR-T

5 years ago

How hot is Hong Kong's biotech IPO market? Two biotechs just raised $800M total

5 years ago

Pfizer infuses $200M into CStone, scoring a second PD-L1 and outlining a sprawling China pact

5 years ago

SoftBank, Morningside help put US-China AI player on the map with $318M bet

5 years ago

Zai Lab hauls in $761M from Hong Kong IPO to push Zejula, more budding candidates in China — report

5 years ago

Rocked by customs investigation, Legend's CFO takes over as CEO Frank Zhang placed under house arrest

5 years ago

A 'breakthrough' PD-1? From China? FDA says why not for rare cancer

5 years ago

As China's tech giants catch onto biotech, Baidu plots $2B startup focused on diagnosis, AI drug discovery

5 years ago

AbbVie jumps into CD47 game, engineers $3B deal with ambitious Chinese player

5 years ago

Carlyle Group injects $260M into a leading cardio player in China, grabbing a seat at the deals table

5 years ago

Ex-Celgene exec steers his biotech startup to Hong Kong IPO as potential cancer drug launch looms

5 years ago

Connect Biopharma snags $115 million in Series C to develop arsenal of immune modulators

5 years ago

Lilly Asia Ventures leads AstraZeneca spinout's $100M push into China's growing R&D hub in Wuxi

5 years ago

Seven PD-(L)1 players could be vying for a place on China's drug reimbursement list. How far will they go?

5 years ago

Teamed up with Lyell, Juno/WuXi joint venture files IPO betting on China's CAR-T future

5 years ago

CanSino reaps $748M windfall from Shanghai IPO — as it warns Covid-19 vaccine won't be a huge money maker

5 years ago

First page Previous page 15 16 171819 20 21 Next page Last page